The incremental prognostic and clinical value of multiple novel biomarkers in heart failure

European Journal of Heart Failure

Volumn 18, Issue 12, 2016, Pages 1491-1498

  Jackson, Colette E ^a   Haig, Caroline ^b   Welsh, Paul ^a   Dalzell, Jonathan R ^a   Tsorlalis, Ioannis K ^a   McConnachie, Alex ^b   Preiss, David ^a   Anker, Stefan D ^c   Sattar, Naveed ^a   Petrie, Mark C ^d   Gardner, Roy S ^d   McMurray, John J V ^a  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

^b UNIVERSITY OF GLASGOW   (United Kingdom)

^c UNIVERSITY MEDICAL CENTER GÖTTINGEN   (Germany)

^d GOLDEN JUBILEE NATIONAL HOSPITAL   (United Kingdom)

Author keywords

Heart failure; Novel biomarkers; Prognosis; Risk stratification

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ATRIAL NATRIURETIC FACTOR; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; C REACTIVE PROTEIN; COPEPTIN; CYSTATIN C; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; GALECTIN 3; MINERALOCORTICOID ANTAGONIST; PROADRENOMEDULLIN; TROPONIN T; ADRENOMEDULLIN; BIOLOGICAL MARKER; GLYCOPEPTIDE; IL1RL1 PROTEIN, HUMAN; INTERLEUKIN 1 RECEPTOR LIKE 1 PROTEIN; MID-REGIONAL PRO-ADRENOMEDULLIN, HUMAN; PEPTIDE FRAGMENT; PROTEIN PRECURSOR;

ADULT; AGED; APOPTOSIS; ARTICLE; CARDIAC MUSCLE CELL; CELL DAMAGE; CELL STRESS; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE MARKER; EXTRACELLULAR MATRIX; FEMALE; FOLLOW UP; HEART FAILURE; HOSPITAL PATIENT; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MALE; MORTALITY; OUTCOME ASSESSMENT; PREDICTION; PREDICTIVE VALUE; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY; RECEIVER OPERATING CHARACTERISTIC; REFERENCE VALUE; RISK ASSESSMENT; HEART STROKE VOLUME; METABOLISM; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROPORTIONAL HAZARDS MODEL; VERY ELDERLY;

ADRENOMEDULLIN; AGED; AGED, 80 AND OVER; ATRIAL NATRIURETIC FACTOR; BIOMARKERS; C-REACTIVE PROTEIN; CYSTATIN C; FEMALE; FOLLOW-UP STUDIES; GALECTIN 3; GLYCOPEPTIDES; HEART FAILURE; HUMANS; INTERLEUKIN-1 RECEPTOR-LIKE 1 PROTEIN; MALE; MIDDLE AGED; MORTALITY; MULTIVARIATE ANALYSIS; PEPTIDE FRAGMENTS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; PROTEIN PRECURSORS; ROC CURVE; STROKE VOLUME; TROPONIN T;

EID: 84964555800     PISSN: 13889842     EISSN: 18790844     Source Type: Journal    
DOI: 10.1002/ejhf.543     Document Type: Article

References (20)

1. Allen LA, Stevenson LW, Grady KL, Goldstein NE, Matlock DD, Arnold RM, Cook NR, Felker M, Francis GS, Hauptman PJ, Havranek EP, Krumholz HM, Mancini D, Riegel B, Spertus JA. Decision making in advanced heart failure a scientific statement from the American Heart Association. Circulation 2012;125:1928–1952.
2. Ponikowski P, Anker SD, AlHabib KF, Cowie MR, Force TL, Hu S, Jaarsma T, Krum H, Rastogi V, Rohde LE, Samal UC, Shimokawa H, Siswanto BB, Sliwa K, Filippatos G. Heart failure: preventing disease and death worldwide. ESC Heart Fail 2014;1 4–25.
3. Ahmad T, Fiuzat M, Pencina MJ, Geller NL, Zannad F, Cleland JG, Snider JV, Blankenberg S, Adams KF, Redberg RF, Kim JB, Mascette A, Mentz RJ, O'Connor CM, Felker GM, Januzzi JL. Charting a roadmap for heart failure studies. JACC Heart Fail 2014;2:477–488.
4. van Kimmenade RR, Januzzi JL Jr. Emerging biomarkers in heart failure. Clin Chem 2012;58 127–138.
5. Lassus J, Gayat E, Mueller C, Peacock WF, Spinar J, Harjola VP, van Kimmenade R, Pathak A, Mueller T, Disomma S, Metra M, Pascual-Figal D, Laribi S, Logeart D, Nouira S, Sato N, Potocki M, Parenica J, Collet C, Cohen-Solal A, Januzzi JL Jr, Mebazza A; GREAT-Network. Incremental value of biomarkers to clinical variables for mortality prediction in acutely decompensated heart failure: the Multinational Observational Cohort on Acute Heart Failure (MOCA) study. Int J Cardiol 2013;168: 2186–2194.
6. Jackson CE, Myles RC, Tsorlalis IK, Dalzell JR, Spooner RJ, Rodgers JR, Bezlyak V, Greenlaw N, Ford I, Cobbe SM, Petrie MC, McMurray JJ. Profile of microvolt T-wave alternans testing in 1003 patients hospitalized with heart failure. Eur J Heart Fail 2012;14:377–386.
7. McMurray JJ, Adamopoulos S, Anker SD, Auricchio A, Bohm M, Dickstein K, Falk V, Filippatos G, Fonseca C, Gomez-Sanchez MA, Jaarsma T, Kober L, Lip GY, Maggioni AP, Parkhomenko A, Pieske BM, Popescu BA, Ronnevik PK, Rutten FH, Schwitter J, Seferovic P, Stepinska J, Trindade PT, Voors AA, Zannad F, Zeiher A. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012. Eur Heart J 2012;33:1787–1847.
8. Paulus WJ, Tschope C, Sanderson JE, Rusconi C, Flachskampf FA, Rademakers FE, Marino P, Smiseth OA, De Keulenaer G, Leite-Moreira AF, Borbely A, Edes I, Handoko ML, Heymans S, Pezzali N, Pieske B, Dickstein K, Fraser AG, Brutsaert DL. How to diagnose diastolic heart failure: a consensus statement on the diagnosis of heart failure with normal left ventricular ejection fraction by the Heart Failure and Echocardiography Associations of the European Society of Cardiology. Eur Heart J 2007;28:2539–2550.
9. Pocock SJ, Wang D, Pfeffer MA, Yusuf S, McMurray JJ, Swedberg KB, Ostergren J, Michelson EL, Pieper KS, Granger CB. Predictors of mortality and morbidity in patients with chronic heart failure. Eur Heart J 2006;27:65–75.
10. Felker GM, Allen LA, Pocock SJ, Shaw LK, McMurray JJ, Pfeffer MA, Swedberg K, Wang D, Yusuf S, Michelson EL, Granger CB. Red cell distribution width as a novel prognostic marker in heart failure: data from the CHARM Program and the Duke Databank. J Am Coll Cardiol 2007;50:40–47.
11. Allen LA, Felker GM, Pocock S, McMurray JJ, Pfeffer MA, Swedberg K, Wang D, Yusuf S, Michelson EL, Granger CB; CHARM Investigators. Liver function abnormalities and outcome in patients with chronic heart failure: data from the Candesartan in Heart Failure: Assessment of Reduction in Mortality and Morbidity (CHARM) program. Eur J Heart Fail 2009;11:170–177.
12. Harrell FE, Lee KL, Mark DB. Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med 1996;15: 361–387.
13. Heagerty PJ, Lumley T, Pepe MS. Time-dependent ROC curves for censored survival data and a diagnostic marker. Biometrics 2000;56:337–344.
14. Pencina MJ, D'Agostino RB Sr, D, Agostino RB Jr, Vasan RS. Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond. Stat Med. 2008;27:157–172.
15. Pencina, MJ, D'Agostino RB, Steyerberg EW. Extensions of net reclassification improvement calculations to measure usefulness of new biomarkers. Stat Med 2011;30:11–21.
16. Gegenhuber A, Struck J, Dieplinger B, Poelz W, Pacher R, Morgenthaler NG, Bergmann A, Haltmayer M, Mueller T. Comparative evaluation of B-type natriuretic peptide, mid-regional pro-A-type natriuretic peptide, mid-regional pro-adrenomedullin, and copeptin to predict 1-year mortality in patients with acute destabilized heart failure. J Card Fail 2007;13:42–49
17. Pascual-Figal DA, Casas T, Ordonez-Llanos J, Manzano-Fernández S, Bonaque JC, Boronat M, Muñoz-Esparza C, Valdés M, Januzzi JL. Highly sensitive troponin T for risk stratification of acutely destabilized heart failure. Am Heart J 2012;163:1002–1010.
18. Ky B, French B, McCloskey K, Eduardo Rame J, McIntosh E, Shahi P, Dries DL, Wilson Tang WH, Wu AH, Fang JC, Boxer R, Sweitzer NK, Levy WC, Goldberg LR, Jessup M, Cappola T. High-sensitivity ST2 for prediction of adverse outcomes in chronic heart failure. Circ Heart Fail 2011;4: 180–187.
19. Kalogeropoulos AP, Wilson Tang WH, Hsu A, Felker GM, Hernandez AF, Troughton RW, Voors AA, Anker SD, Metra M, McMurray JJ, Massie BM, Ezekowitz JA, Califf RM, O'Connor CM, Starling RC, Butler J. high-sensitivity C-reactive protein in acute heart failure: insights from the ASCEND-HF trial. J Card Fail 2014;20:319–326.
20. Jackson CE, Haig C, Welsh P, Dalzell JR, Tsorlalis IK, McConnachie A, Preiss D, McInnes IB, Sattar N, Petrie MC, Gardner RS, McMurray JJ. Combined free light chains are novel predictors of prognosis in heart failure. JACC Heart Fail 2015;3:618–625.